Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation
In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT r...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2016-10, Vol.51 (10), p.1313-1317 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1317 |
|---|---|
| container_issue | 10 |
| container_start_page | 1313 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 51 |
| creator | Tsirigotis, P Danylesko, I Gkirkas, K Shem-Tov, N Yerushalmi, R Stamouli, M Avigdor, A Spyridonidis, A Gauthier, J Goldstein, G Apostolidis, J Mohty, M Shimoni, A Nagler, A |
| description | In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients. |
| doi_str_mv | 10.1038/bmt.2016.129 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1827923913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A465515234</galeid><sourcerecordid>A465515234</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-8dac28d966cfcb66eb9e7195519b0f985511279979538cf652c72e499ba4a6353</originalsourceid><addsrcrecordid>eNqNkl2L1DAUhoMo7jh657UUBPHCjvlo0uRyXdQVFrzR65Cm6UzXNqlJqs5f8dd6ul1lFBEhkK_nvCfn5EXoMcE7gpl82Yx5RzERO0LVHbQhVS1KzgS_izaYClkyJtQZepDSNcakqjC_j85oTSTDim_Q91fR-Tx_60fTFF9cG3LvCxg2jE3vTe6DL772-VCEeDOHORdt8LAbjuN0CPaYHfDdnBayg_MJgkAyrWGXod1_Ar2VHk1huuxiYYYh7J13vS1SdmNh3TAUORqfpsH4fJP3IbrXmSG5R7fzFn188_rDxWV59f7tu4vzq9JywnMpW2OpbJUQtrONEK5RriaKc6Ia3CkJC0JrpWrFmbSd4NTW1FVKNaYygnG2Rc9X3SmGz7NLWY99Wh5kvAtz0kRCOGWKsP9BhZBCwsds0dM_0OswRw-FaCoqSmqJVf0vCrS4lHUtTrT2ZnAauh2gVXZJrc8rAQVyyiqgnp1QB2eGfEhhmJdept_BFytoY0gpuk5PEf4_HjXBevGUBk_pxVMaPAX4k9s3zs3o2l_wTxMBUK5Agiu_d_GkiL8J_gBog9Y3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1825887760</pqid></control><display><type>article</type><title>Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Tsirigotis, P ; Danylesko, I ; Gkirkas, K ; Shem-Tov, N ; Yerushalmi, R ; Stamouli, M ; Avigdor, A ; Spyridonidis, A ; Gauthier, J ; Goldstein, G ; Apostolidis, J ; Mohty, M ; Shimoni, A ; Nagler, A</creator><creatorcontrib>Tsirigotis, P ; Danylesko, I ; Gkirkas, K ; Shem-Tov, N ; Yerushalmi, R ; Stamouli, M ; Avigdor, A ; Spyridonidis, A ; Gauthier, J ; Goldstein, G ; Apostolidis, J ; Mohty, M ; Shimoni, A ; Nagler, A</creatorcontrib><description>In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2016.129</identifier><identifier>PMID: 27183095</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67 ; 692/699/1541/1990/291/1556 ; Adolescent ; Adult ; Autografts ; Bone marrow ; Brentuximab vedotin ; Care and treatment ; Cell Biology ; Combined Modality Therapy ; Dosage and administration ; Fatalities ; Female ; Graft vs Host Disease - drug therapy ; Graft vs Host Disease - etiology ; Graft-versus-host reaction ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic Stem Cell Transplantation - methods ; Hodgkin Disease - complications ; Hodgkin Disease - mortality ; Hodgkin Disease - therapy ; Hodgkin's disease ; Hodgkin's lymphoma ; Humans ; Immunoconjugates - administration & dosage ; Immunoconjugates - adverse effects ; Immunosuppression ; Immunotherapy ; Internal Medicine ; Lymphocyte Transfusion ; Lymphocytes ; Lymphoma ; Male ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; original-article ; Patients ; Public Health ; Stem cell transplantation ; Stem Cells ; Steroid hormones ; Steroids - therapeutic use ; Survival Analysis ; Targeted cancer therapy ; Transplantation ; Treatment Outcome ; Young Adult</subject><ispartof>Bone marrow transplantation (Basingstoke), 2016-10, Vol.51 (10), p.1313-1317</ispartof><rights>Macmillan Publishers Limited 2016</rights><rights>COPYRIGHT 2016 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Oct 2016</rights><rights>Macmillan Publishers Limited 2016.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-8dac28d966cfcb66eb9e7195519b0f985511279979538cf652c72e499ba4a6353</citedby><cites>FETCH-LOGICAL-c515t-8dac28d966cfcb66eb9e7195519b0f985511279979538cf652c72e499ba4a6353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/bmt.2016.129$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/bmt.2016.129$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27183095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsirigotis, P</creatorcontrib><creatorcontrib>Danylesko, I</creatorcontrib><creatorcontrib>Gkirkas, K</creatorcontrib><creatorcontrib>Shem-Tov, N</creatorcontrib><creatorcontrib>Yerushalmi, R</creatorcontrib><creatorcontrib>Stamouli, M</creatorcontrib><creatorcontrib>Avigdor, A</creatorcontrib><creatorcontrib>Spyridonidis, A</creatorcontrib><creatorcontrib>Gauthier, J</creatorcontrib><creatorcontrib>Goldstein, G</creatorcontrib><creatorcontrib>Apostolidis, J</creatorcontrib><creatorcontrib>Mohty, M</creatorcontrib><creatorcontrib>Shimoni, A</creatorcontrib><creatorcontrib>Nagler, A</creatorcontrib><title>Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients.</description><subject>631/67</subject><subject>692/699/1541/1990/291/1556</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Autografts</subject><subject>Bone marrow</subject><subject>Brentuximab vedotin</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Combined Modality Therapy</subject><subject>Dosage and administration</subject><subject>Fatalities</subject><subject>Female</subject><subject>Graft vs Host Disease - drug therapy</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft-versus-host reaction</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hodgkin Disease - complications</subject><subject>Hodgkin Disease - mortality</subject><subject>Hodgkin Disease - therapy</subject><subject>Hodgkin's disease</subject><subject>Hodgkin's lymphoma</subject><subject>Humans</subject><subject>Immunoconjugates - administration & dosage</subject><subject>Immunoconjugates - adverse effects</subject><subject>Immunosuppression</subject><subject>Immunotherapy</subject><subject>Internal Medicine</subject><subject>Lymphocyte Transfusion</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>original-article</subject><subject>Patients</subject><subject>Public Health</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Steroid hormones</subject><subject>Steroids - therapeutic use</subject><subject>Survival Analysis</subject><subject>Targeted cancer therapy</subject><subject>Transplantation</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkl2L1DAUhoMo7jh657UUBPHCjvlo0uRyXdQVFrzR65Cm6UzXNqlJqs5f8dd6ul1lFBEhkK_nvCfn5EXoMcE7gpl82Yx5RzERO0LVHbQhVS1KzgS_izaYClkyJtQZepDSNcakqjC_j85oTSTDim_Q91fR-Tx_60fTFF9cG3LvCxg2jE3vTe6DL772-VCEeDOHORdt8LAbjuN0CPaYHfDdnBayg_MJgkAyrWGXod1_Ar2VHk1huuxiYYYh7J13vS1SdmNh3TAUORqfpsH4fJP3IbrXmSG5R7fzFn188_rDxWV59f7tu4vzq9JywnMpW2OpbJUQtrONEK5RriaKc6Ia3CkJC0JrpWrFmbSd4NTW1FVKNaYygnG2Rc9X3SmGz7NLWY99Wh5kvAtz0kRCOGWKsP9BhZBCwsds0dM_0OswRw-FaCoqSmqJVf0vCrS4lHUtTrT2ZnAauh2gVXZJrc8rAQVyyiqgnp1QB2eGfEhhmJdept_BFytoY0gpuk5PEf4_HjXBevGUBk_pxVMaPAX4k9s3zs3o2l_wTxMBUK5Agiu_d_GkiL8J_gBog9Y3</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Tsirigotis, P</creator><creator>Danylesko, I</creator><creator>Gkirkas, K</creator><creator>Shem-Tov, N</creator><creator>Yerushalmi, R</creator><creator>Stamouli, M</creator><creator>Avigdor, A</creator><creator>Spyridonidis, A</creator><creator>Gauthier, J</creator><creator>Goldstein, G</creator><creator>Apostolidis, J</creator><creator>Mohty, M</creator><creator>Shimoni, A</creator><creator>Nagler, A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20161001</creationdate><title>Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation</title><author>Tsirigotis, P ; Danylesko, I ; Gkirkas, K ; Shem-Tov, N ; Yerushalmi, R ; Stamouli, M ; Avigdor, A ; Spyridonidis, A ; Gauthier, J ; Goldstein, G ; Apostolidis, J ; Mohty, M ; Shimoni, A ; Nagler, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-8dac28d966cfcb66eb9e7195519b0f985511279979538cf652c72e499ba4a6353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>631/67</topic><topic>692/699/1541/1990/291/1556</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Autografts</topic><topic>Bone marrow</topic><topic>Brentuximab vedotin</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Combined Modality Therapy</topic><topic>Dosage and administration</topic><topic>Fatalities</topic><topic>Female</topic><topic>Graft vs Host Disease - drug therapy</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft-versus-host reaction</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hodgkin Disease - complications</topic><topic>Hodgkin Disease - mortality</topic><topic>Hodgkin Disease - therapy</topic><topic>Hodgkin's disease</topic><topic>Hodgkin's lymphoma</topic><topic>Humans</topic><topic>Immunoconjugates - administration & dosage</topic><topic>Immunoconjugates - adverse effects</topic><topic>Immunosuppression</topic><topic>Immunotherapy</topic><topic>Internal Medicine</topic><topic>Lymphocyte Transfusion</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>original-article</topic><topic>Patients</topic><topic>Public Health</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Steroid hormones</topic><topic>Steroids - therapeutic use</topic><topic>Survival Analysis</topic><topic>Targeted cancer therapy</topic><topic>Transplantation</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsirigotis, P</creatorcontrib><creatorcontrib>Danylesko, I</creatorcontrib><creatorcontrib>Gkirkas, K</creatorcontrib><creatorcontrib>Shem-Tov, N</creatorcontrib><creatorcontrib>Yerushalmi, R</creatorcontrib><creatorcontrib>Stamouli, M</creatorcontrib><creatorcontrib>Avigdor, A</creatorcontrib><creatorcontrib>Spyridonidis, A</creatorcontrib><creatorcontrib>Gauthier, J</creatorcontrib><creatorcontrib>Goldstein, G</creatorcontrib><creatorcontrib>Apostolidis, J</creatorcontrib><creatorcontrib>Mohty, M</creatorcontrib><creatorcontrib>Shimoni, A</creatorcontrib><creatorcontrib>Nagler, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsirigotis, P</au><au>Danylesko, I</au><au>Gkirkas, K</au><au>Shem-Tov, N</au><au>Yerushalmi, R</au><au>Stamouli, M</au><au>Avigdor, A</au><au>Spyridonidis, A</au><au>Gauthier, J</au><au>Goldstein, G</au><au>Apostolidis, J</au><au>Mohty, M</au><au>Shimoni, A</au><au>Nagler, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>51</volume><issue>10</issue><spage>1313</spage><epage>1317</epage><pages>1313-1317</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>27183095</pmid><doi>10.1038/bmt.2016.129</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2016-10, Vol.51 (10), p.1313-1317 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1827923913 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature; EZB-FREE-00999 freely available EZB journals |
| subjects | 631/67 692/699/1541/1990/291/1556 Adolescent Adult Autografts Bone marrow Brentuximab vedotin Care and treatment Cell Biology Combined Modality Therapy Dosage and administration Fatalities Female Graft vs Host Disease - drug therapy Graft vs Host Disease - etiology Graft-versus-host reaction Hematology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - methods Hodgkin Disease - complications Hodgkin Disease - mortality Hodgkin Disease - therapy Hodgkin's disease Hodgkin's lymphoma Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Immunosuppression Immunotherapy Internal Medicine Lymphocyte Transfusion Lymphocytes Lymphoma Male Medicine Medicine & Public Health Monoclonal antibodies original-article Patients Public Health Stem cell transplantation Stem Cells Steroid hormones Steroids - therapeutic use Survival Analysis Targeted cancer therapy Transplantation Treatment Outcome Young Adult |
| title | Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A45%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brentuximab%20vedotin%20in%20combination%20with%20or%20without%20donor%20lymphocyte%20infusion%20for%20patients%20with%20Hodgkin%20lymphoma%20after%20allogeneic%20stem%20cell%20transplantation&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Tsirigotis,%20P&rft.date=2016-10-01&rft.volume=51&rft.issue=10&rft.spage=1313&rft.epage=1317&rft.pages=1313-1317&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/bmt.2016.129&rft_dat=%3Cgale_proqu%3EA465515234%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1825887760&rft_id=info:pmid/27183095&rft_galeid=A465515234&rfr_iscdi=true |